Purpose: This study aimed to evaluate the contrast-enhanced ultrasound with Sonazoid (Sonazoid-CEUS) features of hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD).Methods: In this retrospective study, patients who underwent surgical resection and were histopathologically diagnosed with NAFLD or cirrhosis-related HCC were included. All patients received Sonazoid-CEUS examinations within 1 week prior to hepatic surgery. The enhancement patterns of HCC lesions were evaluated and compared between the two groups according to the current World Federation for Ultrasound in Medicine and Biology guidelines. Multivariate logistic regression analysis was used to assess the correlations between Sonazoid-CEUS enhancement patterns and clinicopathologic characteristics.Results: From March 2022 to April 2023, a total of 151 patients with HCC were included, comprising 72 with NAFLD-related HCC and 79 with hepatitis B virus (HBV) cirrhosis–related HCC. On Sonazoid-CEUS, more than half of the NAFLD-related HCCs exhibited relatively early and mild washout within 60 seconds (54.2%, 39/72), whereas most HBV cirrhosis–related HCCs displayed washout between 60 and 120 seconds (46.8%, 37/79) or after 120 seconds (39.2%, 31/79) (P<0.001). In the patients with NAFLD-related HCC, multivariate analysis revealed that international normalized ratio (odds ratio [OR], 0.002; 95% confidence interval [CI], 0.000 to 0.899; P=0.046) and poor tumor differentiation (OR, 21.930; 95% CI, 1.960 to 245.319; P=0.012) were significantly associated with washout occurring within 60 seconds.Conclusion: Characteristic Sonazoid-CEUS features are useful for diagnosing HCC in patients with NAFLD.
Purpose: This study was performed to evaluate the diagnostic performance of ultrasound-derived fat fraction (UDFF) for detecting hepatic steatosis in patients with steatotic liver disease (SLD), using liver biopsy and histopathology as the gold standard.Methods: In this prospective study, patients referred for evaluation of suspected SLD were enrolled. All patients underwent UDFF and controlled attenuation parameter (CAP) measurements. Histopathological findings were assessed using the steatosis-activity-fibrosis scoring system as the gold standard. Pearson or Spearman correlation analyses and multivariate linear regression were performed. Areas under the receiver operating characteristic curves (AUCs) were utilized to assess the diagnostic performance of UDFF and CAP in identifying hepatic steatosis. The DeLong test was used to compare AUCs. Results: From February 2023 to May 2025, 66 patients were included. The median body mass index was 24 kg/m2. UDFF was positively correlated with hepatic steatosis grade (r=0.66). Using UDFF thresholds of 9.5%, 14.5%, and 16.3% (determined by the Youden index), the AUCs for detecting steatosis grades ≥S1, ≥S2, and S3 were 0.82, 0.90, and 0.99, respectively. UDFF exhibited a significantly higher AUC than CAP for detecting steatosis grade S3 (P=0.037). UDFF was correlated with hepatic steatosis grade, activity grade, CAP, aspartate aminotransferase level, and albumin level (all P<0.05). Conclusion: UDFF demonstrated good diagnostic performance for assessing hepatic steatosis, using histopathology as the reference. UDFF may serve as a quantitative imaging approach to measure liver fat content in patients with SLD.